Peter Reichardt
Overview
Explore the profile of Peter Reichardt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
184
Citations
7805
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roohani S, Krcek R, Reichardt P
Strahlenther Onkol
. 2025 Feb;
PMID: 40019495
No abstract available.
2.
Waldschmidt J, Haug L, Riedhammer C, Deinzer C, Zimmermann M, Heidemeier A, et al.
Front Oncol
. 2025 Jan;
14:1518775.
PMID: 39886672
Background: Dedifferentiated liposarcoma (DDLPS) is a rare mesenchymal cancer originating from the adipose tissue, with poor survival rates for most patients, highlighting the critical need for novel treatment options. Case...
3.
Roohani S, Handtke J, Hummedah K, Albertsmeier M, Andreou D, Apostolidis L, et al.
J Cancer Res Clin Oncol
. 2025 Jan;
151(1):30.
PMID: 39755880
Purpose: The management of soft tissue sarcoma (STS) at reference centers with specialized multidisciplinary tumor boards (MTB) improves patient survival. The German Cancer Society (DKG) certifies sarcoma centers in German-speaking...
4.
Joensuu H, Reichardt A, Eriksson M, Hohenberger P, Boye K, Cameron S, et al.
Br J Cancer
. 2024 Jun;
131(2):299-304.
PMID: 38862742
Background: Patients with ruptured gastrointestinal stromal tumour (GIST) have poor prognosis. Little information is available about how adjuvant imatinib influences survival. Methods: We explored recurrence-free survival (RFS) and overall survival...
5.
Gelderblom H, Bhadri V, Stacchiotti S, Bauer S, Wagner A, van de Sande M, et al.
Lancet
. 2024 Jun;
403(10445):2709-2719.
PMID: 38843860
Background: Tenosynovial giant cell tumour (TGCT) is a locally aggressive neoplasm for which few systemic treatment options exist. This study evaluated the efficacy and safety of vimseltinib, an oral, switch-control,...
6.
Niethard M, Knebel C, Leithner A, Tunn P, Schoon J, Reichardt P, et al.
Cancers (Basel)
. 2024 May;
16(9).
PMID: 38730585
Primary leiomyosarcoma of bone (LMSoB) is extremely rare, comprising only <0.7% of primary malignant bone tumors, and is therefore considered an ultra-rare tumor entity. There is currently no consensus as...
7.
Roohani S, Ehret F, Beck M, Veltsista D, Nadobny J, Zschaeck S, et al.
Int J Hyperthermia
. 2024 Apr;
41(1):2342348.
PMID: 38653548
Purpose: To analyze the current practice of regional hyperthermia (RHT) for soft tissue sarcoma (STS) at 12 European centers to provide an overview, find consensuses and identify controversies necessary for...
8.
Kasper B, Pink D, Rothermundt C, Richter S, Augustin M, Kollar A, et al.
Cancers (Basel)
. 2024 Feb;
16(3).
PMID: 38339308
E-TRAB was a non-interventional, prospective trial investigating the feasibility and predictive value of geriatric assessments (GA) in older STS patients treated with trabectedin as first-line therapy. Primary endpoints were overall...
9.
Thuss-Patience P, Hogner A, Goekkurt E, Stahl M, Kretzschmar A, Gotze T, et al.
JAMA Netw Open
. 2024 Jan;
7(1):e2352830.
PMID: 38261316
Importance: Adding immune checkpoint inhibitors to chemotherapy has been associated with improved outcomes in metastatic esophagogastric adenocarcinoma, but treatment combinations and optimal patient selection need to be established. Objective: To...
10.
Pogkas A, Reichardt P, Tunn P, Niethard M, Werner M, Ghani S
Oncologist
. 2023 Dec;
29(4):e544-e552.
PMID: 38141181
Background: Primary therapy of localized myxofibrosarcoma (MFS) remains controversial. Primary resection is complicated by a high rate of local recurrence, and the refractoriness to non-surgical treatment results in a higher...